drugset / Trial / NCT01941407
First Line Metastatic Breast Cancer Treatment (ESMERALDA)
NaSingle-groupOpen-labelTreatment
Summary
The efficacy of eribulin is now well known in metastatic breast cancer. Furthermore, a phase III combine study ( chemo + bev)in metastatic first line shown a gain in PFS with no extra toxicities. It could be interesting to explore the combination of bev + eribulin in first line metastatic breast cancer.
Timeline
- Start
- 2013-11
- Primary completion
- 2014-08
- Completion
- 2016-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Eribulin | Small molecule | 1.23 mg/m2 | Intravenous |